Trial Profile
Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhaled Compared to Placebo in Patients With Non-Cystic Fibrosis Bronchiectasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ciprofloxacin (Primary)
- Indications Bacterial infections; Bronchiectasis; Respiratory tract infections
- Focus Therapeutic Use
- Sponsors Bayer
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 17 May 2011 Results presented at the 107th International Conference of the American Thoracic Society, according to a Bayer Healthcare media release.